title: Targeted drug therapy for meningiomas.
abstract: Although advances in surgery, radiation therapy, and stereotactic radiosurgery have significantly improved the treatment of meningiomas, there remains an important subset of patients whose tumors are refractory to conventional therapy. Treatment with traditional chemotherapeutic agents has provided minimal benefit. In this review, the role of targeted molecular therapies for recurrent or progressive meningiomas is discussed.
authors.affiliation: Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Norden
authors.forename: Jan
authors.initials: J
authors.lastname: Drappatz
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D008579:Meningioma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors